drugset
drugset / Trial / NCT01694472

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

NCT01694472 ↗

Phase 1 Unknown 15 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelSupportive care

Summary

The purpose of this study is to evaluate the clinical safety and preliminary efficacy of MAGE-A4 TCR Gene-Modified T lymphocytes in the treatment of malignant solid tumor patients, such as malignant melanoma and lung cancer.

Timeline

Start
2012-07
Primary completion
2016-11
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MAGE-A4 TCR Gene-Modified T Cells Cell therapy 1e+09 cells —
Subject MAGE-A4 TCR Gene-Modified T Cells Cell therapy 3e+09 cells —
Subject MAGE-A4 TCR Gene-Modified T Cells Cell therapy 8e+09 cells —

Indications

cancer